Skip to main content

Advertisement

SpringerLink
Log in

Cerebral tubercular lesions in a patient treated with Infliximab for Crohn’s disease

  • LETTER TO THE EDITORS
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schuna AA, Megaff C (2000) New drugs for the treatment of rheumatoid arthritis. Am J Health Syst Pharm 57:225–234

    PubMed  CAS  Google Scholar 

  2. Kornbluth A (1998) Infliximab approved for use in Crohn’s disease: a report on the FDAGI advisory committee conference. Inflamm Bowel Dis 4:328–329

    Article  PubMed  CAS  Google Scholar 

  3. Braun J, Sieper J (2004) Biological therapies in the spondyloarthropaties – the current state. Rheumatology 43:1072–1084

    Article  PubMed  CAS  Google Scholar 

  4. Greenberg S (2002) Infections in the immunocompromised rheumatologic patient. Crit Care Clin 18:931–936

    Article  PubMed  Google Scholar 

  5. (2004) Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor-Alpha-California, 2002–2003. MMWR 53(30):683–686

  6. Gardam MA, Keystone EC, Menzies R, et al. (2003) Anti tumor necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 3:148–155

    Article  PubMed  CAS  Google Scholar 

  7. Ubukata M, Takayanagi N, Yanagisawa T, et al. (2005) Pulmonary tuberculosis with cerebellar lesion in a patient after anti-TNF-alpha (infliximab) treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi 43(4):247–251

    PubMed  Google Scholar 

  8. Ormerod LP, Milburn HG, Gillespie S, Ledingham S, Rampton D (2005) BTS recommendation for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF alpha treatment. Thorax 60:800–805

    Article  Google Scholar 

  9. (2006) Joint Committee on Vaccination and Immunization Tuberculin Testing. In: Vaccination and immunization. Chapter 32: London: HMSO

  10. Keane J, Gershon S, Wise RP, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factoralpha neutralizing agent. N Engl J Med 345:1098–1104

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Infectious Diseases Division, National Institute for Infectious Diseases, “Lazzaro Spallanzani”, Rome, Italy

    V. Galati, E. Grilli & N. Petrosillo

  2. Diagnostic Department-Radiology, National Institute for Infectious Diseases, “Lazzaro Spallanzani”, Rome, Italy

    E. Busi Rizzi

  3. Gastroenterology Unit, San Camillo Hospital, Rome, Italy

    C. Prantera

Authors
  1. V. Galati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Grilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Busi Rizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Prantera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Petrosillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Galati.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galati, V., Grilli, E., Busi Rizzi, E. et al. Cerebral tubercular lesions in a patient treated with Infliximab for Crohn’s disease. J Neurol 255, 1981–1982 (2008). https://doi.org/10.1007/s00415-008-0042-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-0042-4

Keywords

Search

Navigation